{
    "2019-06-24": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Why These Innovative Biotech ETFs Soaring",
                "features": {
                    "keywords": [
                        "Innovative",
                        "Biotech",
                        "ETFs",
                        "Soaring"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Comparing PFE’s and BMY’s Revenue Trajectory",
                "features": {
                    "keywords": [
                        "PFE",
                        "BMY",
                        "Revenue",
                        "Trajectory"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Stock",
                        "Whale",
                        "Pfizer",
                        "Gene",
                        "Therapy",
                        "Data"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "What Analysts Recommend for Pfizer and Bristol-Myers Squibb",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommend",
                        "Pfizer",
                        "Bristol-Myers",
                        "Squibb"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "BioMarin Gets $15M From Pfizer on Talzenna's European Nod",
                "features": {
                    "keywords": [
                        "BioMarin",
                        "Pfizer",
                        "Talzenna",
                        "European",
                        "Nod"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "U.S. Senate Takes on Big Tech, Plus &quot;Merger Monday&quot;",
                "features": {
                    "keywords": [
                        "U.S.",
                        "Senate",
                        "Big",
                        "Tech",
                        "Merger",
                        "Monday"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Eldorado to Buy Caesars",
                "features": {
                    "keywords": [
                        "Eldorado",
                        "Buy",
                        "Caesars"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "gaming"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Pfizer's Talzenna Gets Approval in Europe for Breast Cancer",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Talzenna",
                        "Approval",
                        "Europe",
                        "Breast",
                        "Cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Read This Before You Buy Any New Cancer Drug Stocks",
                "features": {
                    "keywords": [
                        "Read",
                        "Cancer",
                        "Drug",
                        "Stocks"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}